Psoriasis

On Tuesday, U.S. stocks experienced a positive trading session. The Dow Jones Industrial Average climbed over 480 points, marking a 0.99% increase to 49,462.08. The NASDAQ also saw gains, rising 0.65% to 23,547.17, while the S&P 500 increased by 0.62% to 6,944.82. These are the top stocks that...

Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17....

A new study suggests that some lesser-known cannabinoids in hemp and marijuana can help with common skin conditions like psoriasis, eczema and acne. A study published by the journal 'Molecules' aptly notes, “Dermatological diseases pose a significant burden on the...

Roivant Sciences Ltd's (NASDAQ: ROIV) subsidiary Dermavant Sciences announced results from Phase 3 PSOARING 3 long-term extension study of tapinarof cream 1% for plaque psoriasis in adults. The results demonstrated durable improvements across efficacy outcomes, quality...

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would be released in Q2 2022.  Earlier, the data were anticipated in Q1 of 2022....

Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program.  The Company said it has already planned...

Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin cells.  Piclidenoson is the company's lead drug candidate for the treatment of psoriasis. The company's...

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR).  This additional capital further strengthens Arcutis' balance sheet before a potential 2022 FDA approval & launch of topical roflumilast...

The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) marketing application seeking approval for roflumilast cream for psoriasis in adults and adolescents.  The FDA assigned the application a Prescription Drug User Fee Act target action date of July 29, 2022....

The FDA has approved Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.  With this expanded indication, Otezla is now the first and only oral treatment approved in adult...

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Piclidenoson at the beginning of January 2022.  Piclidenoson is a novel, first-in-...

vTv Therapeutics Inc (NASDAQ: VTVT) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here. As a part of the restructuring, the company will reduce its workforce by approximately 65%. The company also...

Amgen Inc (NASDAQ: AMGN) announced topline results from the DISCREET trial Phase 3 trial of Otezla (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis.  The study showed that oral Otezla 30 mg twice daily achieved a...

The FDA has accepted for review Bristol Myers Squibb & Co's (NYSE: BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. The European Medicines Agency has also validated the deucravacitinib marketing application for plaque...

Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102 is an investigational, novel human VH antibody fragment targeting the IL-17A cytokine. In efficacy...